Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-4 of 4

Sort by

Sort Order Select

Journal Articles

Survival prediction in relapsed/refractory B-cell lymphoma treated with CAR-T therapy: An AI-optimized cox regression model based on CCL5, scgf-β, and TRAIL

Hu Qian, Zekai Mao, Anqi Zhang, Xiaoying Zhang, Xingcheng Yang, Juan Peng, Jiaqi Guo, Liting Chen, Hui Luo, Li Zhu, Xiaoxi Zhou, Yang Yang, Na Wang, Jue Wang, Yicheng Zhang, Jia Wei

Blood (2025) 146 (Supplement 1): 4115.

https://doi.org/10.1182/blood-2025-4115

Published: 2025

Journal Articles

Long-term follow-up reveals sustained benefit of dual CD19/CD22 CAR T-cell therapy alone or combined with autologous stem cell transplantation in TP53-altered relapsed/refractory B-cell non-Hodgkin lymphoma

Juan Peng, Zekai Mao, Yang Cao, Na Wang, Jue Wang, Yang Yang, Jinghuan Xu, Fankai Meng, Liting Chen, Xia Mao, Jiaqi Guo, Xiaoxi Zhou, Yicheng Zhang, Jia Wei

Blood (2025) 146 (Supplement 1): 3712.

https://doi.org/10.1182/blood-2025-3712

Published: 2025

Journal Articles

Outcomes of Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma (r/r B-NHL) Patients with TP53 Gene Disruption Treated with CD19/22 Cocktail CAR T-Cell Therapy Alone or Incorporated with Autologous Stem Cell Transplantation (ASCT)

JIA Wei, Min Xiao, Zekai Mao, Yang Cao, Yi Xiao, Fankai Meng, Yicheng Zhang, Jianfeng Zhou, Liang Huang

Blood (2021) 138 (Supplement 1): 94.

https://doi.org/10.1182/blood-2021-147278

Published: 2021

Journal Articles

Anti CD19/22 Cocktail CAR T-Cell Therapy Can Improve the Outcomes of Patients with TP53-Mutated Relapsed/Refractory B-Cell Lymphoma

JIA Wei, MDPhD, Min Xiao, Zekai Mao, Na Wang, MD PhD, Chunrui Li, MDPhD, Yang Cao, Weimin Sun, Yi Xiao, Chaojiang Gu, Shangkun Zhang, PhD, Yicheng Zhang, Tongcun Zhang, PhD, Jianfeng Zhou, MD PhD, Liang Huang, MD

Blood (2020) 136 (Supplement 1): 43.

https://doi.org/10.1182/blood-2020-138947

Published: 2020

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Survival prediction in relapsed/refractory B-cell lymphoma treated with CAR-T therapy: An AI-optimized cox regression model based on CCL5, scgf-β, and TRAIL

Long-term follow-up reveals sustained benefit of dual CD19/CD22 CAR T-cell therapy alone or combined with autologous stem cell transplantation in TP53-altered relapsed/refractory B-cell non-Hodgkin lymphoma

Outcomes of Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma (r/r B-NHL) Patients with TP53 Gene Disruption Treated with CD19/22 Cocktail CAR T-Cell Therapy Alone or Incorporated with Autologous Stem Cell Transplantation (ASCT)

Anti CD19/22 Cocktail CAR T-Cell Therapy Can Improve the Outcomes of Patients with TP53-Mutated Relapsed/Refractory B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Survival prediction in relapsed/refractory B-cell lymphoma treated with CAR-T therapy: An AI-optimized cox regression model based on CCL5, scgf-β, and TRAIL

Long-term follow-up reveals sustained benefit of dual CD19/CD22 CAR T-cell therapy alone or combined with autologous stem cell transplantation in TP53-altered relapsed/refractory B-cell non-Hodgkin lymphoma

Outcomes of Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma (r/r B-NHL) Patients with TP53 Gene Disruption Treated with CD19/22 Cocktail CAR T-Cell Therapy Alone or Incorporated with Autologous Stem Cell Transplantation (ASCT)

Anti CD19/22 Cocktail CAR T-Cell Therapy Can Improve the Outcomes of Patients with TP53-Mutated Relapsed/Refractory B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only